PT  - JOURNAL ARTICLE
AU  - Anike, Sochima
AU  - Bennett, Paige
TI  - Yttrium-90 transarterialradioembolization: the making of a successful liver-directed therapy.
DP  - 2021 May 01
TA  - Journal of Nuclear Medicine
PG  - 2034--2034
VI  - 62
IP  - supplement 1
4099  - http://jnm.snmjournals.org/content/62/supplement_1/2034.short
4100  - http://jnm.snmjournals.org/content/62/supplement_1/2034.full
SO  - J Nucl Med2021 May 01; 62
AB  - 2034Objectives: 1. Highlight the basis for use of Trans-arterial Radio-embolization in liver oncologic interventions. 2. Highlight indications and contraindications of Yttrium-90 Trans-arterial Radio-embolization in management of primary and secondary liver malignancies. 3. Elucidate pre-treatment planning, treatment, and post-treatment assessment of patients undergoing Yttrium-90 Trans-arterial Radio-embolization. 4. Present sample case of routine Yttrium-90 Trans-arterial Radio-embolization in patient with hepatic malignancy. 5. Highlight sample cases that demonstrate contraindications to Yttrium-90 Trans-arterial Radio-embolization from findings during pre-treatment planning. Abstract: Yttrium-90 Trans-arterial Radio-embolization (Y-90 TARE) has gained increasing application in multidisciplinary management of primary and secondary hepatic malignancies. The unique vascular signature of hepatic malignancies, when compared to normal liver parenchyma, lends itself to liver-directed trans-arterial therapies. Meticulous pre-treatment planning prior to Y-90 TARE improve the odds of achieving desired treatment goal while minimizing non-target distribution of Y-90 microspheres with resulting adverse outcomes. In FDG-avid tumors, FDG PET/CT, could play an important role in pre-treatment characterization of tumor burden as well as post-treatment assessment of tumor response to treatment [1].